Aprea Therapeutics, Inc.
$0.98
▲
1.65%
2026-04-21 05:21:00
aprea.com
NCM: APRE
Explore Aprea Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$11.45 M
Current Price
$0.98
52W High / Low
$2.22 / $0.55
Stock P/E
—
Book Value
$1.52
Dividend Yield
—
ROCE
-100.49%
ROE
-74.58%
Face Value
—
EPS
$-1.93
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
8
Beta
1.57
Debt / Equity
—
Current Ratio
5.63
Quick Ratio
5.63
Forward P/E
-1.39
Price / Sales
36.74
Enterprise Value
$-3.37 M
EV / EBITDA
0.26
EV / Revenue
-11.8
Rating
Strong Buy
Target Price
$4.4
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Maze Therapeutics, Inc. | $26.84 | — | $1.4 B | — | -38.15% | -47.52% | $53.65 / $7.16 | $7.2 |
| 2. | Ocugen, Inc. | $1.85 | — | $606.61 M | — | -307.31% | -7.77% | $2.73 / $0.64 | $-0.04 |
| 3. | Curanex Pharmaceuticals Inc | $0.48 | — | $12.79 M | — | -37.04% | -85.25% | $9.18 / $0.26 | $0.01 |
| 4. | Alpha Cognition Inc. Common Stock | $6.89 | — | $150.02 M | — | -23.03% | -40.68% | $11.54 / $3.97 | $2.88 |
| 5. | Actinium Pharmaceuticals, Inc. | $1.44 | — | $42.98 M | — | -82.74% | -1.67% | $1.95 / $0.95 | $0.25 |
| 6. | Cardiff Oncology, Inc. | $1.78 | — | $123.06 M | — | -107.63% | -71.45% | $4.55 / $1.48 | $0.66 |
| 7. | Nektar Therapeutics | $100.35 | — | $2.87 B | — | -57.64% | -2.18% | $109 / $7.99 | $4.41 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -2.64 M | -3.12 M | -3.39 M | -4.09 M | -3.23 M |
| Net Profit | -2.46 M | -2.97 M | -3.24 M | -3.93 M | -2.89 M |
| EPS in Rs | -0.21 | -0.26 | -0.28 | -0.34 | -0.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -13.23 M | -14.32 M | -15.47 M | -37.37 M |
| Net Profit | -12.6 M | -12.96 M | -14.29 M | -112.66 M |
| EPS in Rs | -1.1 | -1.13 | -1.25 | -9.84 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 15.93 M | 23.98 M | 22.65 M | 30.16 M |
| Total Liabilities | 3.49 M | 4.67 M | 5.7 M | 4.51 M |
| Equity | 12.44 M | 19.31 M | 16.95 M | 25.64 M |
| Current Assets | 15.56 M | 23.58 M | 22.52 M | 30.15 M |
| Current Liabilities | 2.76 M | 3.36 M | 4.39 M | 3.2 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -12.89 M | -13.56 M | -12.18 M | -25.01 M |
| Investing CF | 0 M | -0.02 M | -0.09 M | 0 M |
| Financing CF | 4.64 M | 14.82 M | 5.14 M | 0.68 M |
| Free CF | -12.89 M | -13.57 M | -12.27 M | -25.01 M |
| Capex | — | -0.02 M | -0.09 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 9.3% | 87.32% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-02-13 | 1:0.05 |